Harmonizing Definitions for Progression Independent of Relapse Activity in Multiple Sclerosis A Systematic Review

被引:61
|
作者
Mueller, Jannis [1 ,2 ,3 ,4 ]
Cagol, Alessandro [1 ,2 ,3 ]
Lorscheider, Johannes [1 ,2 ,4 ]
Tsagkas, Charidimos [1 ,2 ,3 ,4 ]
Benkert, Pascal [5 ]
Yaldizli, Ozgur [1 ,2 ,3 ,4 ]
Kuhle, Jens [1 ,2 ,4 ]
Derfuss, Tobias [1 ,2 ,4 ]
Sormani, Maria Pia [6 ,7 ]
Thompson, Alan [8 ,9 ]
Granziera, Cristina [1 ,2 ,3 ,4 ]
Kappos, Ludwig [1 ,2 ,3 ,10 ]
机构
[1] Univ Hosp Basel, Res Ctr Clin Neuroimmunol & Neurosci Basel RC2NB, Basel, Switzerland
[2] Univ Basel, Basel, Switzerland
[3] Univ Hosp Basel, Fac Med, Dept Biomed Engn, Translat Imaging Neurol ThINK Basel, Basel, Switzerland
[4] Univ Hosp Basel, Dept Biomed, Neurol Clin & Policlin, Basel, Switzerland
[5] Univ Basel, Univ Hosp Basel, Dept Clin Res, Clin Trial Unit, Basel, Switzerland
[6] IRCCS Osped Policlin San Martino, Dept Hlth Sci, I-16132 Genoa, Italy
[7] IRCCS Osped Policlin San Martino, Genoa, Italy
[8] UCL Inst Neurol, Queen Sq MS Ctr, London, England
[9] NIHR Univ Coll London Hosp, Biomed Res Ctr, London, England
[10] Res Ctr Clin Neuroimmunol & Neurosci Basel RC2NB, Spitalstr 2, CH-4031 Basel, Switzerland
关键词
DISABILITY PROGRESSION; ONSET; PIRA; ACCUMULATION; OCRELIZUMAB; AGE;
D O I
10.1001/jamaneurol.2023.3331
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
ImportanceEmerging evidence suggests that progression independent of relapse activity (PIRA) is a substantial contributor to long-term disability accumulation in relapsing-remitting multiple sclerosis (RRMS). To date, there is no uniform agreed-upon definition of PIRA, limiting the comparability of published studies.ObjectiveTo summarize the current evidence about PIRA based on a systematic review, to discuss the various terminologies used in the context of PIRA, and to propose a harmonized definition for PIRA for use in clinical practice and future trials.Evidence ReviewA literature search was conducted using the search terms multiple sclerosis, PIRA, progression independent of relapse activity, silent progression, and progression unrelated to relapses in PubMed, Embase, Cochrane, and Web of Science, published between January 1990 and December 2022.FindingsOf 119 identified single records, 48 eligible studies were analyzed. PIRA was reported to occur in roughly 5% of all patients with RRMS per annum, causing at least 50% of all disability accrual events in typical RRMS. The proportion of PIRA vs relapse-associated worsening increased with age, longer disease duration, and, despite lower absolute event numbers, potent suppression of relapses by highly effective disease-modifying therapy. However, different studies used various definitions of PIRA, rendering the comparability of studies difficult.Conclusion and RelevancePIRA is the most frequent manifestation of disability accumulation across the full spectrum of traditional MS phenotypes, including clinically isolated syndrome and early RRMS. The harmonized definition suggested here may improve the comparability of results in current and future cohorts and data sets.
引用
收藏
页码:1232 / 1245
页数:14
相关论文
共 50 条
  • [21] Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis
    Elliott, Colm
    Belachew, Shibeshih
    Wolinsky, Jerry S.
    Hauser, Stephen L.
    Kappos, Ludwig
    Barkhof, Frederik
    Bernasconi, Corrado
    Fecker, Julian
    Model, Fabian
    Wei, Wei
    Arnold, Douglas L.
    BRAIN, 2019, 142 : 2787 - 2799
  • [22] Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials
    Kappos, Ludwig
    Wolinsky, Jerry S.
    Giovannoni, Gavin
    Arnold, Douglas L.
    Wang, Qing
    Bernasconi, Corrado
    Model, Fabian
    Koendgen, Harold
    Manfrini, Marianna
    Belachew, Shibeshih
    Hauser, Stephen L.
    JAMA NEUROLOGY, 2020, 77 (09) : 1132 - 1140
  • [23] Disease activity impacts disability progression in primary progressive multiple sclerosis
    Marrodan, M.
    Bensi, C.
    Pappolla, A.
    Rojas, J. I.
    Gaitan, M. I.
    Ysrraelit, M. C.
    Negrotto, L.
    Fiol, M. P.
    Patrucco, L.
    Cristiano, E.
    Farez, M. F.
    Correale, J.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2020, 39
  • [24] Chronic lesion activity and disability progression in secondary progressive multiple sclerosis
    Beynon, Vanessa
    George, Ilena C.
    Elliott, Colm
    Arnold, Douglas L.
    Ke, Jun
    Chen, Huaihou
    Zhu, Li
    Ke, Chunlei
    Giovannoni, Gavin
    Scaramozza, Matthew
    Campbell, Nolan
    Bradley, Daniel P.
    Franchimont, Nathalie
    Gafson, Arie
    Belachew, Shibeshih
    BMJ NEUROLOGY OPEN, 2022, 4 (01)
  • [25] Emerging Cerebrospinal Fluid Biomarkers of Disease Activity and Progression in Multiple Sclerosis
    Cross, Anne H.
    Gelfand, Jeffrey M.
    Thebault, Simon
    Bennett, Jeffrey L.
    von Buedingen, H. Christian
    Cameron, Briana
    Carruthers, Robert
    Edwards, Keith
    Fallis, Robert
    Gerstein, Rachel
    Giacomini, Paul S.
    Greenberg, Benjamin
    Hafler, David A.
    Ionete, Carolina
    Kaunzner, Ulrike W.
    Kodama, Lay
    Lock, Christopher
    Longbrake, Erin E.
    Musch, Bruno
    Pardo, Gabriel
    Piehl, Fredrik
    Weber, Martin S.
    Yuen, Steven
    Ziemssen, Tjalf
    Bose, Gauruv
    Freedman, Mark S.
    Anania, Veronica G.
    Ramesh, Akshaya
    Winger, Ryan C.
    Jia, Xiaoming
    Herman, Ann
    Harp, Christopher
    Bar-Or, Amit
    JAMA NEUROLOGY, 2024, 81 (04) : 373 - 383
  • [26] Validating Predictors of Disease Progression in a Large Cohort of Primary-Progressive Multiple Sclerosis Based on a Systematic Literature Review
    Stellmann, Jan-Patrick
    Neuhaus, Anneke
    Lederer, Christian
    Daumer, Martin
    Heesen, Christoph
    PLOS ONE, 2014, 9 (03):
  • [27] Waist Circumference and Body Mass Index as Predictors of Disability Progression in Multiple Sclerosis: A Systematic Review and Meta-Analysis
    Giannopapas, Vasileios
    Stefanou, Maria-Ioanna
    Smyrni, Vassiliki
    Kitsos, Dimitrios K.
    Kosmidou, Maria
    Stasi, Sophia
    Chasiotis, Athanasios K.
    Stavrogianni, Konstantina
    Papagiannopoulou, Georgia
    Tzartos, John S.
    Paraskevas, George P.
    Tsivgoulis, Georgios
    Giannopoulos, Sotirios
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (06)
  • [28] The global prevalence of familial multiple sclerosis: an updated systematic review and meta-analysis
    Ehtesham, Naeim
    Rafie, Maryam Zare
    Mosallaei, Meysam
    BMC NEUROLOGY, 2021, 21 (01)
  • [29] Contraceptive use among women with multiple sclerosis: a systematic review
    Zapata, Lauren B.
    Oduyebo, Titilope
    Whiteman, Maura K.
    Houtchens, Maria K.
    Marchbanks, Polly A.
    Curtis, Kathryn M.
    CONTRACEPTION, 2016, 94 (06) : 612 - 620
  • [30] Safety profile of ocrelizumab for the treatment of multiple sclerosis: a systematic review
    Ng, Huah Shin
    Rosenbult, Constanza Luzon
    Tremlett, Helen
    EXPERT OPINION ON DRUG SAFETY, 2020, 19 (09) : 1069 - 1094